3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
4
Endocrine
4
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
CNS
1
Conditions
Glioma
8
Glioblastoma
7
Recurrence
3
Osteosarcoma
3
Neuroblastoma
3
Medulloblastoma
3
Ependymoma
3
Central Nervous System Neoplasms
3
Wilms Tumor
2
Sarcoma
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Pheochromocytoma
2
Paraganglioma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Lymphoma, Non-Hodgkin
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Cholangiocarcinoma
2
Brain Neoplasms
2
Xanthogranuloma, Juvenile
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Neuroendocrine Tumors
1
Meningioma
1
Histiocytic Sarcoma
1
Gliosarcoma
1
Familial ependymoma
1
Esthesioneuroblastoma, Olfactory
1
Breast Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
7
gallium Ga 68 dotatate
6
lutetium Lu 177 dotatate
4
Fluorodeoxyglucose F18
3
3-Iodobenzylguanidine
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
3
fluorodopa F 18
2
Specimen Handling
2
FAPI-46
2
Everolimus
2
Erlotinib Hydrochloride
2
vandetanib
1
romidepsin
1
pertuzumab
1
pentetreotide
1
olaparib
1
fludarabine phosphate
1
entrectinib
1
dactolisib
1
cabozantinib
1
atezolizumab
1
arginyllysine
1
amino-acid, glucose, and electrolyte solution
1
alectinib
1
Whole Body Imaging
1
Tretinoin
1
Respiratory Therapy
1
Quality of Life
1
Positron-Emission Tomography
1
Patient Reported Outcome Measures
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
olaparib
×
CNS
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled